fluoxetine and mazindol

fluoxetine has been researched along with mazindol in 25 studies

Research

Studies (25)

TimeframeStudies, this research(%)All Research%
pre-19901 (4.00)18.7374
1990's5 (20.00)18.2507
2000's12 (48.00)29.6817
2010's7 (28.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Baldessarini, RJ; Booth, RG; Charifson, PS; Kula, NS; McPhail, AT; Myers, AM; Owens, CE; Wyrick, SD1
Cortizo, L; García, N; Innerárity, A; Labeaga, L; Mosquera, R; Orjales, A; Pumar, MC; Toledo, A1
Belardi, JK; Bray, JA; Burroughs, KD; Cohn, ST; Cosmi, SA; Deecher, DC; Gavrin, LK; Ho, DM; Johnston, GH; Koury, EJ; Leiter, J; Leventhal, L; Mahaney, PE; Mugford, CA; Platt, B; Rosenzweig-Lipson, SJ; Sabatucci, JP; Santilli, AA; Smith, VA; Stack, GP; Trybulski, EJ; Vu, TA; Ye, F; Zhang, Y1
Bray, J; Deecher, D; Johnston, G; Koury, E; Mahaney, PE; McComas, CC; Terefenko, EA; Trybulski, E; Vu, A; Zhang, P1
Bray, JA; Cohn, ST; Deecher, DC; Dooley, R; Goljer, I; Johnston, GH; Leiter, J; Mahaney, PE; Moore, WJ; Terefenko, EA; Trybulski, EJ; Vu, AT; Zhang, P1
Deecher, DC; Ho, DM; Kim, CY; Mahaney, PE; Manas, E; McConnell, O; Trybulski, EJ; Zhang, Y1
Bray, J; Deecher, D; Fensome, A; Harrison, J; Kim, C; Koury, E; Mahaney, PE; Mark, L; McComas, CC; Mugford, CA; Terefenko, EA; Trybulski, EJ; Vu, AT; Whiteside, GT; Zhang, P1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ1
Burroughs, K; Cosmi, S; Deecher, DC; Ho, D; Johnston, G; Leiter, J; Mahaney, PE; Sabatucci, JP; Trybulski, E; Zhang, Y1
Adedoyin, A; Alfinito, PD; Bray, JA; Cosmi, S; Deecher, DC; Fensome, A; Harrison, J; Leventhal, L; Mann, C; McComas, CC; O'Neill, DJ; Spangler, TB; Sullivan, NR; Trybulski, EJ; Uveges, AJ; Whiteside, GT; Zhang, P1
Adedoyin, A; Bray, JA; Deecher, DC; Fensome, A; Goldberg, JA; Harrison, J; Leventhal, L; Mann, C; Mark, L; Nogle, L; O'Neill, DJ; Spangler, TB; Sullivan, NR; Terefenko, EA; Trybulski, EJ; Uveges, AJ; Vu, A; Whiteside, GT; Zhang, P1
Choi, Y; Raymer, BK1
Brodkin, J; Nash, JF1
Angel, I; Claustre, Y; Langer, SZ; Scatton, B; Taranger, MA1
Fuller, RW; Hemrick-Luecke, SK; Snoddy, HD1
Kleven, MS; Woolverton, WL1
Berman, R; Charney, DS; Delgado, PL; Heninger, GR; Krystal, JH; Miller, HL; Salomon, RM1
Czupryniak, L; Drzewoski, J1
Arterburn, D2
Arterburn, D; DeLaet, D; Flum, D1
Adkins, EM; Blakely, RD; Field, JR; Henry, LK; Newman, AH; Parnas, ML; Vaughan, RA; Zou, MF1
Almeida, MQ; Carvalho, DF; Cercato, C; Halpern, A; Mancini, MC1
Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H1

Reviews

5 review(s) available for fluoxetine and mazindol

ArticleYear
Sleep modulating agents.
    Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16

    Topics: Animals; Humans; Sleep; Sleep Aids, Pharmaceutical; Sleep Wake Disorders; Wakefulness-Promoting Agents

2019
Obesity.
    Clinical evidence, 2003, Issue:10

    Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine

2003
Obesity.
    Clinical evidence, 2004, Issue:11

    Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine; Phenylpropanolamine; Selective Serotonin Reuptake Inhibitors

2004
Obesity.
    Clinical evidence, 2005, Issue:13

    Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty; Humans; Lactones; Mazindol; Obesity; Orlistat; Phentermine

2005
[Therapeutical approach of obesity in Prader-Willi Syndrome].
    Arquivos brasileiros de endocrinologia e metabologia, 2007, Volume: 51, Issue:6

    Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Child; Child, Preschool; Female; Fluoxetine; Fructose; Humans; Infant; Infant, Newborn; Male; Mazindol; Obesity; Prader-Willi Syndrome; Selective Serotonin Reuptake Inhibitors; Topiramate

2007

Trials

2 trial(s) available for fluoxetine and mazindol

ArticleYear
Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
    Archives of general psychiatry, 1996, Volume: 53, Issue:2

    Topics: 1-Naphthylamine; Adrenergic Uptake Inhibitors; Antidepressive Agents; Brain; Brain Chemistry; Depressive Disorder; Desipramine; Diphenhydramine; Dopamine; Fluoxetine; Humans; Mazindol; Methyltyrosines; Norepinephrine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline

1996
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
    International journal of obesity (2005), 2014, Volume: 38, Issue:8

    Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Diethylpropion; Female; Fluoxetine; Follow-Up Studies; Humans; Mazindol; Obesity; Prospective Studies; Surveys and Questionnaires; Treatment Outcome; Weight Loss

2014

Other Studies

18 other study(ies) available for fluoxetine and mazindol

ArticleYear
Conformational analysis, pharmacophore identification, and comparative molecular field analysis of ligands for the neuromodulatory sigma 3 receptor.
    Journal of medicinal chemistry, 1994, Nov-25, Volume: 37, Issue:24

    Topics: Animals; Ligands; Models, Molecular; Molecular Conformation; Receptors, sigma; Rodentia; Structure-Activity Relationship; Tetrahydronaphthalenes

1994
Syntheses and binding studies of new [(aryl)(aryloxy)methyl]piperidine derivatives and related compounds as potential antidepressant drugs with high affinity for serotonin (5-HT) and norepinephrine (NE) transporters.
    Journal of medicinal chemistry, 2003, Dec-04, Volume: 46, Issue:25

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Brain; Carrier Proteins; Fluoxetine; In Vitro Techniques; Male; Membrane Glycoproteins; Membrane Transport Proteins; Morpholines; Nerve Tissue Proteins; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Piperidines; Radioligand Assay; Rats; Rats, Wistar; Reboxetine; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Stereoisomerism; Structure-Activity Relationship; Symporters

2003
Structure-activity relationships of the cycloalkanol ethylamine scaffold: discovery of selective norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2008, Jul-10, Volume: 51, Issue:13

    Topics: Animals; Cell Line; Cyclohexanols; Ethylamines; Female; Humans; Male; Mice; Models, Molecular; Molecular Structure; Norepinephrine; Pain; Rats; Structure-Activity Relationship; Symporters

2008
Synthesis and activity of novel 1- or 3-(3-amino-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones as selective norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2008, Dec-01, Volume: 18, Issue:23

    Topics: Benzimidazoles; Combinatorial Chemistry Techniques; Drug Design; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Norepinephrine; Stereoisomerism

2008
3-(Arylamino)-3-phenylpropan-2-olamines as a new series of dual norepinephrine and serotonin reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, May-01, Volume: 19, Issue:9

    Topics: Adrenergic Uptake Inhibitors; Animals; Chemistry, Pharmaceutical; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Design; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Norepinephrine; Propanolamines; Selective Serotonin Reuptake Inhibitors; Structure-Activity Relationship

2009
Discovery of a new series of monoamine reuptake inhibitors, the 1-amino-3-(1H-indol-1-yl)-3-phenylpropan-2-ols.
    Bioorganic & medicinal chemistry letters, 2009, Sep-01, Volume: 19, Issue:17

    Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Cell Line; CHO Cells; Cricetinae; Cricetulus; Crystallography, X-Ray; Dogs; Dopamine Plasma Membrane Transport Proteins; Drug Discovery; Humans; Molecular Conformation; Norepinephrine; Propanols; Recombinant Proteins; Serotonin Plasma Membrane Transport Proteins; Structure-Activity Relationship

2009
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors.
    Journal of medicinal chemistry, 2009, Sep-24, Volume: 52, Issue:18

    Topics: Administration, Oral; Animals; Behavior, Animal; Benzimidazoles; Biological Transport; Dopamine Plasma Membrane Transport Proteins; Female; Humans; Hyperalgesia; Male; Neurotransmitter Uptake Inhibitors; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Propanolamines; Rats; Rats, Sprague-Dawley; Serotonin Plasma Membrane Transport Proteins; Spinal Nerves; Structure-Activity Relationship; Substrate Specificity

2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
    Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6

    Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics

2010
Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors.
    Bioorganic & medicinal chemistry letters, 2010, May-01, Volume: 20, Issue:9

    Topics: Animals; Crystallography, X-Ray; Ethylamines; Humans; Molecular Conformation; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Rats; Structure-Activity Relationship; Thiophenes

2010
Discovery of novel selective norepinephrine reuptake inhibitors: 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231).
    Journal of medicinal chemistry, 2010, Jun-10, Volume: 53, Issue:11

    Topics: Animals; Cell Line; Cyclic S-Oxides; Drug Discovery; Female; Humans; Male; Neurotransmitter Uptake Inhibitors; Norepinephrine; Rats; Structure-Activity Relationship; Thiadiazoles

2010
Discovery of novel selective norepinephrine inhibitors: 1-(2-morpholin-2-ylethyl)-3-aryl-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxides (WYE-114152).
    Journal of medicinal chemistry, 2011, Oct-13, Volume: 54, Issue:19

    Topics: Acute Pain; Administration, Oral; Analgesics; Animals; Benzothiazoles; Biological Availability; Cell Line; Chronic Pain; Cricetinae; Cyclic S-Oxides; Dogs; Humans; Inflammation; Injections, Intravenous; Male; Morpholines; Neuralgia; Norepinephrine Plasma Membrane Transport Proteins; Rats; Stereoisomerism; Thiadiazoles

2011
Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: effect of dopamine uptake inhibitors.
    The Journal of pharmacology and experimental therapeutics, 1991, Volume: 259, Issue:2

    Topics: 3,4-Methylenedioxyamphetamine; Animals; Corpus Striatum; Dialysis; Dopamine; Extracellular Space; Fluoxetine; Ketanserin; Male; Mazindol; N-Methyl-3,4-methylenedioxyamphetamine; Neurotransmitter Uptake Inhibitors; Piperazines; Rats; Rats, Inbred Strains; Serotonin

1991
Anorectic activities of serotonin uptake inhibitors: correlation with their potencies at inhibiting serotonin uptake in vivo and 3H-mazindol binding in vitro.
    Life sciences, 1988, Volume: 43, Issue:8

    Topics: Animals; Appetite Depressants; Eating; Fluoxetine; Indoles; Male; Mazindol; Norepinephrine; Piperidines; Rats; Rats, Inbred Strains; Serotonin; Serotonin Antagonists

1988
Fluoxetine at anorectic doses does not have properties of a dopamine uptake inhibitor.
    Journal of neural transmission. General section, 1994, Volume: 96, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; Amphetamine; Animals; Appetite Depressants; Brain Chemistry; Dopamine; Dopamine Uptake Inhibitors; Fluoxetine; Homovanillic Acid; Injections, Intraventricular; Male; Mazindol; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley

1994
Effects of three monoamine uptake inhibitors on behavior maintained by cocaine or food presentation in rhesus monkeys.
    Drug and alcohol dependence, 1993, Volume: 31, Issue:2

    Topics: 1-Naphthylamine; Animals; Appetitive Behavior; Behavior, Animal; Cocaine; Dose-Response Relationship, Drug; Fluoxetine; Macaca mulatta; Mazindol; Motivation; Reinforcement Schedule; Selective Serotonin Reuptake Inhibitors; Self Administration; Sertraline

1993
[The role of pharmacotherapy for treatment of obesity in adults].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2000, Volume: 9, Issue:53

    Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agonists; Ephedrine; Fluoxetine; Humans; Lactones; Mazindol; Obesity; Orlistat

2000
Tyr-95 and Ile-172 in transmembrane segments 1 and 3 of human serotonin transporters interact to establish high affinity recognition of antidepressants.
    The Journal of biological chemistry, 2006, Jan-27, Volume: 281, Issue:4

    Topics: Adrenergic Uptake Inhibitors; Amino Acid Sequence; Animals; Antidepressive Agents; Binding Sites; Binding, Competitive; Blotting, Western; Cadmium; Cell Line; Cell Membrane; Citalopram; Clomipramine; Cocaine; Cysteine; Dopamine Uptake Inhibitors; Fluoxetine; HeLa Cells; Humans; Immunoprecipitation; Isoleucine; Kinetics; LLC-PK1 Cells; Mazindol; Methionine; Mice; Models, Chemical; Molecular Sequence Data; Mutation; N-Methyl-3,4-methylenedioxyamphetamine; Nomifensine; Protein Binding; Protein Structure, Tertiary; Protein Transport; Radiopharmaceuticals; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Species Specificity; Stereoisomerism; Substrate Specificity; Tyrosine

2006